参考文献
[1]CHEN P, LI Z, HU Y. Prevalence of osteoporosis in China: a meta-analysis and systematic review [J]. BMC public health, 2016, 16(1): 1039.
[2]中国疾病预防控制中心慢病中心. 国家卫生健康委发布中国骨质疏松症流行病学调查结果 [M]. 北京; http://www.chinacdc.cn/gsywlswxx_9498/crbs/201812/t20181217_198289.html. 2018.
[3]ZENG Q, LI N, WANG Q, et al. The Prevalence of Osteoporosis in China, a Nationwide, Multicenter DXA Survey [J]. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019, 34(10): 1789-97.
[4]CUI Z, MENG X, FENG H, et al. Estimation and projection about the standardized prevalence of osteoporosis in mainland China [J]. Archives of osteoporosis, 2019, 15(1): 2.
[5]INTERNATIONAL OSTEOPOROSIS FOUNDATION 国际骨质疏松基金会. 亚太地区年鉴:2013年骨质疏松症的流行病学、花费负担统计结果 [M]. 2013.
[6]WANG O, HU Y, GONG S, et al. A survey of outcomes and management of patients post fragility fractures in China [J]. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2015, 26(11): 2631-40.
[7]SI L, WINZENBERG T M, JIANG Q, et al. Projection of osteoporosis-related fractures and costs in China: 2010-2050 [J]. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2015, 26(7): 1929-37.
[8]INTERNATIONAL OSTEOPOROSIS FOUNDATION 国际骨质疏松基金会. 国际骨质疏松基金会 (IOF) 骨质疏松症纲要 - 第一版 [M]. Nyon Switzerland. 2017.
[9]BONE H G, WAGMAN R B, BRANDI M L, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension [J]. The lancet Diabetes &; endocrinology, 2017, 5(7): 513-23.
[10]CUMMINGS S R, SAN MARTIN J, MCCLUNG M R, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [J]. The New England journal of medicine, 2009, 361(8): 756-65.
[11]MCCLUNG M R, LEWIECKI E M, COHEN S B, et al. Denosumab in postmenopausal women with low bone mineral density [J]. The New England journal of medicine, 2006, 354(8): 821-31.
[12]MILLER P D, PANNACCIULLI N, MALOUF-SIERRA J, et al. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates [J]. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020, 31(1): 181-91.
[13]BROWN J P, PRINCE R L, DEAL C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial [J]. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2009, 24(1): 153-61.
[14]KENDLER D L, ROUX C, BENHAMOU C L, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy [J]. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2010, 25(1): 72-81.
[15]MILLER P D, PANNACCIULLI N, BROWN J P, et al. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates [J]. The Journal of clinical endocrinology and metabolism, 2016, 101(8): 3163-70.
[16]FREEMANTLE N, SATRAM-HOANG S, TANG E T, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women [J]. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, 23(1): 317-26.
[17]GIBIANSKY L, SUTJANDRA L, DOSHI S, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours [J]. Clinical pharmacokinetics, 2012, 51(4): 247-60.
[18]SUTJANDRA L, RODRIGUEZ R D, DOSHI S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis [J]. Clinical pharmacokinetics, 2011, 50(12): 793-807.
[19]夏维波, 章振林, 林华, et al. 原发性骨质疏松症诊疗指南 (2017) [J]. 中国骨质疏松杂志, 2019, 3): 281-309.
[20]CAMACHO P M, PETAK S M, BINKLEY N, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016 [J]. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2016, 22(Suppl 4): 1-42.
[21]CAMACHO P M, PETAK S M, BINKLEY N, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY [J]. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2016, 22(9): 1111-8.
[22]QASEEM A, FORCIEA M A, MCLEAN R M, et al. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians [J]. Ann Intern Med 2017, Jun 6(166-818.
[23]BRIOT K, ROUX C, THOMAS T, et al. 2018 update of French recommendations on the management of postmenopausal osteoporosis [J]. Joint bone spine, 2018, 85(5): 519-30.
[24]EASTELL R, ROSEN C J, BLACK D M, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline [J]. The Journal of clinical endocrinology and metabolism, 2019, 104(5): 1595-622.
[25]LEDER B Z, TSAI J N, UIHLEIN A V, et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial [J]. The Journal of clinical endocrinology and metabolism, 2014, 99(5): 1694-700.
[26]LEDER B Z, TSAI J N, UIHLEIN A V, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial [J]. Lancet (London, England), 2015, 386(9999): 1147-55.